AN2 Therapeutics ANTX 深 沪
等待开盘 08-25 09:30:00 美东时间
5.63
-0.180
-3.10%
华盛通- 最 高5.82
- 今 开5.82
- 成交量 17.14万股
- 最 低 5.59
- 昨 收 5.81
- 总市值 2.12亿
- 52周最高 7.19
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 1.00
- 委 比 84.00%
- 总股本 3773.62万
- 历史最高 23.58
- 量 比 0.73
- 振 幅 3.96%
- 历史最低 0.87
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AN2 Therapeutics appoints biotech veteran Cameron Trenor as CMO
AN2 Therapeutics (ANTX) appointed Cameron Trenor, M.D., as chief medical officer, bringing more than two decades of clinical and drug development experience. Trenor most recently served as chief medic...
08-24 19:44
QUICK SPARK: Russell 2000 Hits New Record Highs, Beats Nasdaq 100 In 2026
The Russell 2000 index just hit a new record high on Thursday, climbing past 3,060 points. The small-cap index, tracked by the iShares Russell 2000 ETF (NYSE:IWM), is now up over 23% year to date, edging ahead of the Nasdaq 100’s 19% gain. The biggest Russell 2000 winners thus far this year are: Bra...
08-13 23:29
AN2 Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
AN2 Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-12 23:34
AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from the same period last year.
08-12 04:33
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.
07-20 20:03
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humansPhase 1 First-In-Human (FIH) study showed
06-04 19:09
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.
05-15 04:35
